Document Detail

Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial.
MedLine Citation:
PMID:  17261383     Owner:  NLM     Status:  MEDLINE    
BACKGROUND & AIMS: The impact of interferon (IFN) treatment on the occurrence of complications related to hepatitis C virus (HCV)-related cirrhosis is debated because the majority of studies are retrospective. We designed a randomized controlled trial comparing the efficacy of prolonged IFN alfa-2a treatment vs nontreatment on complication-free survival in patients with compensated HCV cirrhosis. METHODS: A total of 102 patients (mean age, 60.5 +/- 9.5 y; male/female ratio, .82) with biopsy examination-proven HCV cirrhosis, Child-Pugh score A, who were hepatocellular carcinoma (HCC) free, and had at least 1 risk factor of complications were randomized to receive IFN or no therapy for 24 months. RESULTS: During the follow-up evaluation, the complication rate was 24.5%: HCC occurred in 12 and decompensation unrelated to HCC occurred in 13 patients. The number of HCC patients was similar in both groups. The probability of complication-free survival was not significantly different between treated and untreated patients (98% and 72.3% vs 90% and 70.7% at 12 and 24 mo, respectively, P = .59). The median time until complication occurrence was 17.1 months in the treated group vs 13.6 months in the untreated group (P = .2). CONCLUSIONS: This randomized controlled trial showed that a 2-year course of IFN has little or no impact on complication-free survival in patients with high-risk compensated HCV cirrhosis.
Laetitia Fartoux; Françoise Degos; Christian Trépo; Odile Goria; Paul Calès; Albert Tran; Catherine Buffet; Thierry Poynard; Dominique Capron; Jean-Jacques Raabe; Dominique Roulot; Sylvie Naveau; Jean-Didier Grange; Renée E Poupon; Raoul Poupon; Lawrence Serfaty
Related Documents :
10854823 - Adult beta-thalassemic patients with chronic hepatitis c: long-term efficacy of alpha-i...
15784033 - Efficacy of short-term interferon therapy for patients infected with hepatitis c virus ...
21281033 - Novasure endometrial ablation under local anaesthesia in an outpatient setting: an obse...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2007-01-29
Journal Detail:
Title:  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association     Volume:  5     ISSN:  1542-7714     ISO Abbreviation:  Clin. Gastroenterol. Hepatol.     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-04-20     Completed Date:  2007-05-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160775     Medline TA:  Clin Gastroenterol Hepatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  502-7     Citation Subset:  IM    
AP-HP, Hôpital Saint-Antoine, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / therapeutic use
Confidence Intervals
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Hepatitis C, Chronic / diagnosis,  drug therapy,  mortality*
Interferon Alfa-2a / therapeutic use*
Liver Cirrhosis / drug therapy*,  mortality*,  virology*
Middle Aged
Odds Ratio
Proportional Hazards Models
Prospective Studies
Reference Values
Risk Assessment
Severity of Illness Index
Survival Analysis
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Antiviral Agents; 76543-88-9/Interferon Alfa-2a
Comment In:
Clin Gastroenterol Hepatol. 2007 Apr;5(4):427-9   [PMID:  17445750 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Beta-carotene from cassava (Manihot esculenta Crantz) leaves improves vitamin A status in rats.
Next Document:  Analysis of lignans from Phyllanthus niruri L. in plasma using a simple HPLC method with fluorescenc...